Tag: BIO HEA MTC PHA

Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer

Target Action (PDUFA) Date set for October 7, 2025 Application based on data from IMforte, the first Phase 3 trial demonstrating statistically significant and clinically...

Highlights in Oral Presentation of Mabwell’s 9MW2821 at 2025 ASCO

SHANGHAI, June 5, 2025 /PRNewswire/ -- At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA, from May 30 to...

- A word from our sponsors -

HomeTagsBIO HEA MTC PHA

Manulife Asia Care Survey 2026: Independence as Asia’s New Legacy

Manulife Asia Care Survey 2026: Independence as Asia’s New Legacy

CARPL.ai Partners with Enlitic to Accelerate AI Validation for Imaging Customers

Tag: BIO HEA MTC PHA

Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer

Highlights in Oral Presentation of Mabwell’s 9MW2821 at 2025 ASCO

Explore

Press Releases

News & Opinion

Living

Others

Follow us